Search / Trial NCT06616194

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Launched by PFIZER · Sep 24, 2024

Trial Information

Current as of October 07, 2024

Not yet recruiting

Keywords

Chronic Migraine Adolescents Rimegepant,

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * At least a 6 month history of migraine (with or without aura)
  • * 15 or more headache days/month
  • * 8 or more migraine days/month
  • * Migraine lasting 4-72 hours if untreated
  • Exclusion Criteria:
  • * Unrelenting headache
  • * Current psychiatric condition uncontrolled or untreated
  • * History of suicidal behavior or the subject is at risk of self-harm
  • * History of alcohol abuse and/or illicit drug use
  • * History of severe drug allergy
  • * Use of more than one medication for migraine prevention/prophylaxis
  • * Participation in another clinical trial at the same time

About Pfizer

Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0